TIGIT Inhibitors Market Poised for Strong Growth Through 2034, Driven by Expanding Immuno-Oncology Pipeline | DelveInsight [Yahoo! Finance]
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences (NYSE:RCUS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Arcus Biosciences (NYSE:RCUS) was upgraded by analysts at
Wall Street Ze
Arcus Biosciences (NYSE:RCUS) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating.